Stock Traders Purchase Large Volume of Call Options on Medidata Solutions (MDSO)
Medidata Solutions Inc (NASDAQ:MDSO) was the recipient of unusually large options trading on Friday. Stock investors bought 846 call options on the company. This is an increase of 1,310% compared to the typical volume of 60 call options.
Several research firms have recently issued reports on MDSO. KeyCorp reaffirmed a “buy” rating and issued a $86.00 target price on shares of Medidata Solutions in a report on Sunday, September 17th. Royal Bank of Canada began coverage on Medidata Solutions in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $82.00 target price for the company. Zacks Investment Research raised Medidata Solutions from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. SunTrust Banks reaffirmed a “buy” rating and issued a $92.00 target price on shares of Medidata Solutions in a report on Friday, October 27th. Finally, Wells Fargo & Co reduced their target price on Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $84.54.
In other news, Director Robert Taylor sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $71.39, for a total value of $356,950.00. Following the completion of the transaction, the director now directly owns 49,372 shares of the company’s stock, valued at $3,524,667.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Rouven Bergmann sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $65.40, for a total value of $130,800.00. Following the completion of the transaction, the chief financial officer now directly owns 91,775 shares of the company’s stock, valued at $6,002,085. The disclosure for this sale can be found here. Insiders have sold a total of 239,010 shares of company stock valued at $16,437,036 over the last three months. Corporate insiders own 5.80% of the company’s stock.
Medidata Solutions (NASDAQ:MDSO) opened at $66.90 on Monday. Medidata Solutions has a twelve month low of $47.77 and a twelve month high of $85.92. The firm has a market capitalization of $3,910.00, a price-to-earnings ratio of 95.57, a price-to-earnings-growth ratio of 3.47 and a beta of 1.69. The company has a current ratio of 1.29, a quick ratio of 3.37 and a debt-to-equity ratio of 0.61.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.02. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. The business had revenue of $140.08 million during the quarter, compared to analyst estimates of $141.27 million. During the same period in the prior year, the company earned $0.28 earnings per share. Medidata Solutions’s revenue was up 16.7% compared to the same quarter last year. equities research analysts predict that Medidata Solutions will post 0.78 EPS for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/15/stock-traders-purchase-large-volume-of-call-options-on-medidata-solutions-mdso.html.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.